Everest Medicines Announces Approval of Xerava in China for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients

Xerava approval marks the first product to be commercialized by Everest in China Everest plans to commercially launch Xerava in China in Q3, 2023 Everest Medicines a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the National Medical Products Administration (NMPA) of China has approved its New Drug Application (NDA) for Xerava (eravacycline) for the treatment of complicated intra-abdominal infections (cIAI) in adult patients. The Company plans to commercially launch Xerava in China in the third quarter this year. "We are very excited to receive NMPA approval for Xerava and launch the product as the first product Everest will commercialize in China," said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "This will lead Everest's transformation from a biotech to a fully-integrated biopharmaceutical company. We expect to have three or more product approvals in 2023-2024, including Nefecon to be approved and commercialized later this year. Together with Xerava, these products will help Everest develop into a full commercial-stage company." "The approval of Xerava by NMPA reinforces the importance of addressing the urgent need for innovative antibiotic treatment options in China as multidrug-resistant bacteria infection continues to pose clinical challenges in China," said Sunny Zhu, Chief Medical Officer for Infectious Diseases at Everest Medicines. "We are encouraged by the continued regulatory success of Xerava across our territories in Asia, demonstrating Everest's superior capabilities to effectively advance innovative treatment options on behalf of patients in need. In the infectious disease space, we have other best-in-class product candidates in the pipeline. We plan to file NDA for Taniborbactam in China this year for complicated urinary tract infection and we plan to initiate phase III clinical study in the second half of this year for EVER206, a novel polymyxin derivative with potentially better safety profile compared to current options. We hope to advance these two drug candidates quickly so that our portfolio of three innovative antibiotics could help address the significant unmet medical needs in China." Xerava has been approved and commercialized in Singapore. It was also approved in Hong Kong and is currently under regulatory review for cIAI in the Taiwan region. Since 2020, Xerava has been recommended in multiple global treatment guidelines issued by Infectious Disease Society of America's (IDSA) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) as a treatment choice for multi-drug resistant gram-negative bacterial infections including Carbapenem resistant organisms. In addition, it was included in an expert consensus on the multi-disciplinary management of intra-abdominal infections by the Chinese Society of Surgery of Chinese Medical Association, Infectious Diseases Society for Evidence-based and Translational Medicine of Chinese Research Hospital Association and the Editorial Board of Chinese Journal of Surgery. In Feb. 2023, Xerava was also recommended in the Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli. "Xerava, with a broad bacterial spectrum coverage, shows high antibacterial potency in vitro, and has strong antibacterial activity against major clinical resistant pathogens such as ESBLs, CRE, CRAB, VRE, MRSA, etc.," said Professor Wang Minggui, head of the Institute of Antibiotics at Huashan Hospital affiliated to Fudan University. "Xerava has been recommended by many guidelines in China and abroad, and its domestic launch will definitely help the treatment of resistant pathogens' infections in China." Everest Medicines has exclusive rights to develop and commercialize Xerava in Greater China, South Korea, and certain markets of South East Asia, under a licensing agreement with Tetraphase Pharmaceuticals, Inc. (a wholly owned subsidiary of Innoviva, Inc.).Xerava

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!